Press "Enter" to skip to content

Arrowhead Pharmaceuticals RNAi based Biotech Drug Development

Arrowhead Pharmaceuticals is a leader in RNAi based Biotech Drug Development. The company is systematically tackling drug treatments for a range of diseases based on its unified platform.

The company said that the Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Arrowhead Pharmaceuticals is led by Dr. Christopher Anzalone who is the Chief Operating Officer. Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007. He has a background combining scientific expertise and venture capital exposure to the biotech field.

The pharmaceutical business is that of a methodical innovator and category pioneer. It implements RNAi platform-based research in multiple investigative drug development projects. The goal is to be a leader in an RNAi-based solution to disease. It has developed a marvelous platform to advance multiple beneficial drugs to help patients affected by a variety of serious diseases.

This research and the related trials and phases towards approval of a specific drug costs a lot of money. Arrowood Pharmaceuticals considerable cash is the byproduct of partnerships with other major pharmaceutical companies such as Johnson & Johnson Amgen and Japan’s Takeda. The cash involved was $300 million upfront, with a total value of just over one billion dollars.

Be First to Comment

Leave a Reply

Your email address will not be published.